anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
KEY POINTS: Individuals receiving hemodialysis have high rates of cardiovascular disease not explained by traditional cardiovascular risk factors. Intradialytic exercise improves cardiovascular outcomes, including arterial resistance, BP, and heart rate variability. Clinicians should consider including intradialytic aerobic exercise programs in hemodialysis care to supplement broader treatment plans.
BACKGROUND: Cardiovascular disease is the leading cause of death among people with kidney failure on hemodialysis, for whom improving cardiovascular health is a research priority. Intradialytic myocardial stunning is common and associated with adverse cardiovascular events. Intradialytic exercise may mitigate intradialytic myocardial stunning and improve cardiovascular structure and function. This systematic review investigated the effect of intradialytic exercise on cardiovascular outcomes in adults undergoing maintenance hemodialysis (PROSPERO CRD42018103118).
METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we systematically searched MEDLINE, Embase, Cochrane CENTRAL, SportDiscus, and PEDro databases from 1960 until June 2022, for randomized and nonrandomized studies investigating the effect of intradialytic exercise programs on objective cardiovascular outcomes, prespecified as primary or secondary outcomes. The primary outcome was arterial resistance.
RESULTS: Of 10,837 references identified, 32 met eligibility criteria. These studies investigated the effect of intradialytic exercise on arterial resistance (eight studies), BP (20 studies), myocardial structure and function (seven studies), endothelial function (two studies), sympathetic overactivity (nine studies), biomarkers of cardiac injury (three studies), and cardiovascular hospitalization and mortality (two studies). Most studies used aerobic exercise as the intervention and usual care (no exercise) controls. Meta-analysis of intradialytic exercise versus usual care resulted in a statistically significant reduction in arterial resistance measured by pulse wave velocity with mean difference −1.63 m/s (95% confidence interval, −2.51 to −0.75). Meta-analyses for diastolic BP, left ventricular ejection fraction, and low-frequency/high-frequency ratio measure of heart rate variability also showed statistically significant improvements with exercise. There was no significant difference in change in systolic BP, augmentation index, and left ventricular mass index between groups.
CONCLUSIONS: Intradialytic exercise programming resulted in a clinically meaningful improvement to pulse wave velocity, a component of arterial resistance. Improvements in several physiologic measures of cardiovascular health, including diastolic BP, left ventricular ejection fraction, and heart rate variability measured by the low-frequency/high-frequency ratio were also observed. The effects of intradialytic exercise on major adverse cardiovascular events remains uncertain.
Design: randomized controlled clinical trial with non-pharmacologic intervention. Subjects and setting of study: patients with breast cancer who initiate adjuvant, neoadjuvant or palliative chemotherapy, in the Day Unit of a University Hospital. Interventions: random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist in Medical Oncology before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation. Determinations: use of health resources (not programmed attendance in Primary, Specialist and Emergency care or hospitalisation). Toxicity caused by the chemotherapy. Patients who leave the chemotherapy by serious toxicity. Quality of life measured by means of the EORTC QOL-C30 questionnaire. Satisfaction with the received medical assistance.
Cardiogenic shock (CS) is the most severe form of acute heart failure, with in-hospital mortality up to 50%. Failure to improve mortality has been reported, despite observed improvements in hemodynamics. Previous studies on CS have almost exclusively been focused on CS following an acute coronary syndrome (ACS). Chronic heart failure patients with acute decompensation (ADHF) and CS represent a unique physiologic phenotype compared with ACS patients, which may lead to a differential response to device therapy. Recent evidences emphasize that intra-aortic balloon pump (IABP) is not recommended for patients with ACS-related CS, but it is associated with a high likelihood of bridge to durable Left Ventricular Assist Device or heart transplant without the need for escalation to more potent temporary mechanical circulatory support devices, when implanted in ADHF patients. Data retrieved from the available literature in the setting of patients with CS not related to ACS are poor even in large, well-reported registries.

Accordingly, Altshock-2 trial has been designed to test the superiority of early IABP implantation at admission over local clinical practice (pharmacological only) in ADHF patients with CS, with respect to 60-day survival or successful bridge to heart replacement therapies
This study aimed to elucidate the roles of microRNA (miR)-4738-3p and the collagen type I alpha 2 chain (COL1A2) gene in the pathogenesis of osteoarthritis (OA) through bioinformatics analysis and cellular assays. The GSE55235 dataset was analyzed using the weighted gene co-expression network analysis (WGCNA) method to identify gene modules associated with OA. Key overlapping genes were identified from these modules and the GSE55235-differential expressed genes (DEGs). The expression levels of selected genes were determined in C28/I2 cells using the quantitative real-time polymerase chain reaction (qRT-PCR). The interaction between miR-4738-3p and COL1A2 was examined in the context of interleukin 1 beta (IL-1β) induction. Exosome characterization was achieved through transmission electron microscopy (TEM), western blotting (WB), and other analyses. The study also investigated the functional relevance of miR-4738-3p in OA pathology through various molecular and cellular assays. Our findings revealed that the green module exhibited a strong correlation with the OA phenotype in the GSE55235 dataset, with COL1A2 emerging as a hub gene and miR-4738-3p as its key downstream target. IL-1β induction suggested that COL1A2 is involved in inflammation and apoptosis, while miR-4738-3p appeared to play an antagonistic role. The analysis of exosomes underscored the significance of miR-4738-3p in cellular communication, with an enhanced level of exo-miR-4738-3p antagonizing IL-1β-induced inflammation and promoting cell survival. Conversely, a reduction in exo-miR-4738-3p led to increased cell damage. This study established a clear regulatory relationship between miR-4738-3p and COL1A2, with the nuclear factor kappa B (NF-κB) signaling pathway playing a central role in this regulation. The miR-4738-3p significantly influences the OA-associated inflammation, primarily through modulation of COL1A2 and the NF-κB pathway. Therefore, targeting miR-4738-3p offers a potential therapeutic approach for OA, with exosome miR-4738-3p presenting a promising strategy.
PURPOSE: To administer an aerosol medicine from an inexpensive and small-sized container in a most suitable state by the constitution that a patient can inhale a fixed amount of an air without any medicine content through a mouthpiece and then the aerosol medicine is automatically inhaled with a restricted velocity by at least one orifice form a chamber. CONSTITUTION: After the inhaler 100 of a dosage measured under an industrial standard is pushed down, a valve 200 is seated, and closes a space of containing a drug. A lever 300 is held by a pin 180, and held at the position of closing the valve. In order to inhale the drug by a patient, a diaphragm 270 is getting to be shrunk on the space of contained air. When the diaphragm is shrink up to a predetermined point, the lever 300 is release from the pin 180, and then the valve 200 is moved to a secondarily stable position by the bias of a spring 190. In this case, the patient can inhale an air containing an aerosolized drug from the chamber 310 through a mouthpiece 150. A housing chamber 120 is provided with a velocity-restricting orifice 320 at a remote end portion, and the orifice 320 restricts the velocity of inhaling the aerosolized drug at less than 30 little per minute.
For 25 years, the twin pregnancy rate has regularly increased in the majority of European countries and in the United States, by 35% between 1981 and 2006. Increased use of medically assisted procreation and older maternal age are the two main causes. At the present time twin pregnancies represent nearly 20% of premature deliveries. The rate of very premature births (\< 32-34 weeks) is 7 times higher in twin pregnancies than in singleton pregnancies. As prematurity accounts for 75% of neonatal morbidity and mortality, and extreme prematurity is the principal cause of neonatal mortality and of brain sequelae in twins, the search for a preventive treatment appears as a priority in perinatal medicine. The investigators recently showed in a prospective multicenter study that cervical ultrasound at 22 and 27 wks was a better predictive investigation of premature delivery \< 34 wks than digital examination.\[1\] As there is currently no recommended preventive treatment for prematurity in twin pregnancies\[2\], the 2009 guidelines of the College of Obstetricians leave the teams with the option of carrying out systematic cervical ultrasound or not during follow-up investigations.\[3\] Recently in a randomized trial in a population of short-cervix singleton pregnancies, the premature delivery rate decreased by 40% in the pessary group compared with the usual management group.\[4\] In a recent multicenter trial (ProTWIN), while therapeutic efficacy of the pessary (versus usual management) was not demonstrated in the overall group of twin pregnancies, in the short-cervix subgroup (\< 25th percentile of the population) the \< 32 wks delivery rate decreased from 29% to 14% (OR= 0.49 (0.24-0.97) and neonatal morbidity also decreased.\[5\] No other trial of pessary use in short-cervix twin pregnancies was published today. Recently, in a historical comparison of twins with twin-to-twin transfusion syndrome treated with laser, Carreras et al. have showed a decreased rate of preterm delivery with the use of pessary in case of short cervix.\[6\] The investigators wish to set up a randomized multicenter study in France in the population of short-cervix twin pregnancies to show a potential benefit of the pessary compared with simple surveillance.
PURPOSE: An antagonistic composition containing as a main component an extract of Lxeris chinensis var. exhibiting specified antagonistic action against dioxin or dioxin-like compounds is provided. The composition has lower toxicity than synthetic medicines, effectively reduces toxicity of the dioxin-like material and can used as food additives as well as drugs. CONSTITUTION: A pharmaceutical composition contains a pharmaceutically effective amount of a Lxeris chinensis var. extract and a pharmaceutically acceptable carrier and interrupts the action on a signal transduction pathway related with a xenobiotic response element of a dioxin-like compound. The dioxin-like compound is selected from the group consisting of PCDD, PCDF and PCB.
PURPOSE:To obtain inorg. compd. fine particles which efficiently cuts near infrared rays and has transparency and such a decorating effect that the color tone of the particles changes depending on the change of the visual angle or the incident angle of light. CONSTITUTION:This inorg. compd. fine particle contains 60-100wt.% inorg. compd. and its surface has a group of thin chips having a projecting edge. These fine particles are produced, for example, by dissolving or dispersing zinc, monocarboxylic acid, and lactic acid in almedium comprising at least alcohol, and keeping the obtd. mixture at >=100 deg.C to crystallize zinc in the mixture. These fine particles are mixed with a binder component to obtain a coating compsn., mixed with a resin to obtain a resin compsn. or a resin molded body, mixed with pulp to make paper, or added to a cosmetic material.
Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
Arm 2 is the titrated dosing regimen: participants will start cycle 1 with either 100 mg or 75 mg dose of palbociclib or 400 mg or 200 mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant). For cycle 2 and for subsequent cycles, escalation to the indicated dose will be based on treatment tolerance.
BACKGROUND: Ethiopia is one of the world's coffee producers, generating about 192,000 metric tonnes of coffee husks annually as by-products. The material can be used for ruminant diets to improve the nutrient utilisation of animals. However, coffee husk has toxic compounds, which can be minimised through different processing methods. Though the above techniques can minimise the toxicity level of coffee husk and increase the bioavailability of nutrients, there is scanty information on the comparative efficacy of these techniques, especially in ruminant nutrition.
OBJECTIVE: The study was conducted to examine the effect of processed coffee husk on feed intake, nutrient digestibility, body weight changes and profitability of Bonga rams based on natural pasture hay.
METHODS: In the experiment, 24 rams were used, and the rams were grouped into six blocks based on initial body weight (mean BW 21.5 ± 1.01 kg). The rams were quarantined for 21 days, and each ram was randomly assigned to one of the experimental feed treatments in a randomised complete block design (RCBD). The experimental treatment feeds include 400 g conventional concentrate mix (CM) containing Noug seed cake and wheat bran (T1); 200 g boiled coffee husk + 200 g CM (T2); 200 g roasted coffee husk + 200 g CM (T3) and 200 g raw coffee husk + 200 g CM (T4). The CM was made in the ratio of 1:1. The data collected from the 90-day experimental period were: dry matter and nutrient intakes, initial body weight, final body weight and body weight changes. After the growth experiment, a 7-day digestibility trial was followed by collecting faeces using a harness bag. The data were managed using Microsoft (MS) Excel 2010 and analysed using R software (v. 4.3.2). The chemical compositions of the CM had maximum crude protein (22%), followed by boiled coffee husk (14.74%), which was higher than natural pasture hay (6.91%) and raw coffee husk (12.4%).
RESULTS: The total dry matter intake (p < 0.05), metabolisable energy, and total nutrient intakes of rams were significantly (p < 0.001) maximised when rams fed on boiled coffee husk (T2) than raw (T4) and roasted (T4) coffee husk, except for NDF and organic matter intakes. The apparent digestibility of nutrients and feed conversion efficiency were maximised for rams assigned to T2. There was maximum daily body weight gain (p < 0.001) when rams were supplemented with boiled coffee husk (T2). Also, body weight changes of rams were significantly (p < 0.001) higher for rams supplementation with boiled coffee husk.
CONCLUSION: Therefore, the boiled coffee husk as an alternative feed resource can be replaced by about half of the commercial CM without adverse effects of anti-nutritional factors and enhance the income of smallholder farmers in the coffee crop-livestock production system.
T2DM and prediabetes are characterized by abnormal post-prandial suppression of glucagon, which contributes to postprandial hyperglycemia by increasing endogenous glucose production (EGP). In rodents, altered glucagon signaling changes α-cell function and mass - an effect mediated by changes in circulating AA concentrations. Are the elevated concentrations of branched-chain AA and other AA metabolites in T2DM a cause or an effect of global α-cell dysfunction? To measure glucagon secretion, as well as glucagon action, we have developed a population model of glucagon kinetics allowing us to deconvolve secretion from glucagon concentrations in a manner similar to Van Cauter's model for insulin secretion from C-peptide. This enables better characterization of α-cell function in humans. In addition to our novel methodology, we can characterize α-cell responsiveness to a graded glucose infusion, by quantifying (G50) - the change in glucose concentration necessary to suppress glucagon secretion by 50%. These experiments will determine if the glucagon secretion in response to AA differs in obese individuals with T2DM from that observed in obese individuals without T2DM.
Methods and compositions for the controlled and sustained release of peroxides or oxygen to aqueous environments (e.g. a patient's body or circulatory system, or for other applications) or non-aqueous environments, include a material coating or encapsulating hydrogen peroxide, inorganic peroxides or peroxide adducts. In the case of peroxide adducts, and particularly in one type of embodiment, the peroxide adducts should be able to permeate the material, but water, hydrogen peroxide and inorganic peroxides should be able to permeate the material. The methods and compositions that allow the release of oxygen, H 2 O 2  or inorganic peroxides from peroxide adducts with movement of these moieties across a selectively permeable barrier into, preferably, an aqueous environment. In the case of hydrogen peroxide, it can be acted upon by catalase or other enzymes, or be simply degraded, or are otherwise acted upon by enzymes or catalysts embedded in the selectively permeable barrier to produce, for example, O 2 . Alternatively, hydrogen peroxide or inorganic peroxides can be delivered selectively to a site of action of cleaning, disinfecting or other applications.
Agents for increasing fertility contain kininogenase (e.g. kallikrein, akrosin or trypsin) and/or kinin (e.g. bradykinin or tallidin). They advantageously also contain kininogen (e.g. plasma). The agents are produced by mixing the active ingredients with inert, non-toxic, pharmaceutically suitable carrier substances. The agents increase sperm motility, presumably due to a favourable effect on kinin release in the spermato plasma, and can thus be used to increase the success rate in artificial insemination. Addition of the agents to semen retards ageing processes and restores sperm motility. The agents may also be administered systemically to increase fertility of male animals (incl. humans).
Gait is altered in Parkinson's disease (PD) patients. It has been shown that treadmill training with visual and auditory cues is useful in improving the gait's parameters in patients in early-moderate stages of disease. No data are available about the effectiveness of this training in those subjects in advanced stages of PD. The first aim of this study was to evaluate the effect of a gait training using treadmill with visual and auditory cues in patients in stages IV Hoehn \& Yahr (H\&Y). The second aim was to compare the obtained data of these patients in advanced stages with those in mild to moderate stages.

150 patients with PD in early-moderate and advanced stages of disease (50 in H\&Y stage 2, group 1, 50 in H\&Y stage 3, group 2 and 50 in H\&Y stage 4, group 3) were enrolled. All patients underwent an intensive treatment: 20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
Diethylpropion hydrochloride tablets, 25 mg are schedule IV controlled substances. Diethylpropion hydrochloride has some chemical and pharmacologic similarities to the amphetamines and other related stimulant drugs that have been extensively abused. There have been reports of subjects becoming psychologically dependent on diethylpropion. The possibility of abuse should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with varying degrees of psychologic dependence and social dysfunction which, in the case of certain drugs, may be severe. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.
Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Losartan potassium.

     Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen (BUN) or serum creatinine were observed in less than 0.1 percent of patients with essential hypertension treated with Losartan potassium alone (see PRECAUTIONS, Impaired Renal Function). 

Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.11 grams percent and 0.09 volume percent, respectively) occurred frequently in patients treated with Losartan potassium alone, but were rarely of clinical importance. No patients were discontinued due to anemia.

Liver Function Tests: Occasional elevations of liver enzymes and/or serum bilirubin have occurred. In patients with essential hypertension treated with Losartan potassium alone, one patient (<0.1%) was discontinued due to these laboratory adverse experiences.